<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422679</url>
  </required_header>
  <id_info>
    <org_study_id>CB103-C-101</org_study_id>
    <nct_id>NCT03422679</nct_id>
  </id_info>
  <brief_title>Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies</brief_title>
  <official_title>A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellestia Biotech AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellestia Biotech AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II, non randomized, open-label, dose escalation study to investigate the&#xD;
      safety, tolerability and preliminary efficacy of CB-103.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with&#xD;
      Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed&#xD;
      informed consent, patients will be screened for entry into the study. The study will be&#xD;
      conducted in 2 stages: dose escalation in Part A of the study followed by dose expansion in&#xD;
      Part B (Phase IIA).&#xD;
&#xD;
      Escalation cohorts will receive repeat doses of CB-103 to determine the MTD and RP2D.&#xD;
&#xD;
      CB-103 will be administered orally on a once-daily schedule, based on a 28-day treatment&#xD;
      cycle. Aim of the expansion Phase IIA, Part B of the study will be to collect preliminary&#xD;
      evidence of anti-tumour activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 5, 2017</start_date>
  <completion_date type="Anticipated">December 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Dose limiting toxicity (DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of patients with dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: antitumour efficacy</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Best overall response rates of each tumor type using appropriate response Evaluation Criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A and B: incidence of all adverse events and serious adverse events (safety and tolerability)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of participants with adverse events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: pharmacokinetic - Cmax</measure>
    <time_frame>PK profiling in cycle 1 and 2 (cycle duration: 28 days)</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: pharmacokinetic - tmax</measure>
    <time_frame>PK profiling in cycle 1 and 2 (cycle duration: 28 days)</time_frame>
    <description>Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: pharmacokinetic - AUC</measure>
    <time_frame>PK profiling in cycle 1 and 2 (cycle duration: 28 days)</time_frame>
    <description>Area under the curve during 8 and 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B: pharmacokinetic - t1/2</measure>
    <time_frame>PK profiling in cycle 1 and 2 (cycle duration: 28 days)</time_frame>
    <description>elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: preliminary antitumour efficacy</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Overall response rates of each tumor type using appropriate response evaluation criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Cholangiocellular Carcinoma</condition>
  <condition>Sarcoma</condition>
  <condition>Desmoid Tumour</condition>
  <condition>Adenoid Cystic Carcinoma</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <condition>Glomus Tumor, Malignant</condition>
  <arm_group>
    <arm_group_label>CB-103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-103 capsules will be administered orally as a continuous once daily (QD) dosing during the treatment period of Part A (escalation) and Part B (expansion).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-103</intervention_name>
    <description>Capsules, taken once daily during treatment period A and B. Treatment cycle is 28 days.Starting dose is 15 mg.</description>
    <arm_group_label>CB-103</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Disease&#xD;
&#xD;
               -  Patients with histologically or cytologically confirmed solid tumours that are&#xD;
                  surgically unresectable, locally advanced, or metastatic and whose disease has&#xD;
                  progressed on at least one line of systemic therapy and for whom no standard&#xD;
                  curative therapy exists.&#xD;
&#xD;
               -  The following solid tumour indications are allowed to be enrolled into Part A of&#xD;
                  this study (dose escalation) based on known involvement of the NOTCH pathway&#xD;
                  activation in these indications: Breast cancer (triple negative breast cancer&#xD;
                  [TNBC], ER+/-, HER2+/-), gastrointestinal (GI) cancers (colorectal cancer [CRC],&#xD;
                  cholangiocellular carcinoma [CCC]), sarcomas (osteosarcoma, liposarcoma,&#xD;
                  rhabdomyosarcoma, fibrosarcoma), desmoid tumours, adenoid cystic carcinoma, and&#xD;
                  malignant glomus tumour.&#xD;
&#xD;
               -  Patients with histologically or cytologically confirmed, advanced haematological&#xD;
                  malignancies) whose disease has relapsed or progressed upon standard therapy and&#xD;
                  for whom at that point no standard therapy exists: Non-Hodgkin lymphomas (NHL):&#xD;
                  Follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Burkitt&#xD;
                  lymphoma, marginal zone B cell lymphoma (MZCL), splenic marginal zone lymphoma&#xD;
                  (SMZL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), anaplastic&#xD;
                  large cell lymphoma (ALCL).&#xD;
&#xD;
          2. Demography Men and women ≥ 18 years old on the day of signing informed consent.&#xD;
&#xD;
          3. Organ function and laboratory results&#xD;
&#xD;
             Patients must have the following laboratory values:&#xD;
&#xD;
             a.ANC ≥ 1.5x10^9/L (solid tumour indications) or ≥ 1.0x10^9/L (haematological&#xD;
             malignancies) b.Haemoglobin (Hgb) ≥ 10 g/dL (≥ 100 g/L) c.Platelet count ≥ 75 x 109/L&#xD;
             (no platelet transfusion or growth factor support in the preceding 7d) d.Total serum&#xD;
             bilirubin ≤ 1.5xULN e.ALP ≤ 2.5xULN (if abnormalities are due to the underlying&#xD;
             malignancy and known bone metastases, then ALP must be ≤ 5xULN) f.AST/SGOT and&#xD;
             ALT/SGPT ≤ 2.5xULN (if abnormalities are due to the underlying malignancy and known&#xD;
             hepatic metastases, AST and ALT must be ≤ 5xULN) g.Serum creatinine ≤ 1.5xULN (if&#xD;
             serum creatinine &gt; 1.5xULN, then serum creatinine clearance (CrCl) ≥ 50 mL/min h to k:&#xD;
             Potassium, Total calcium (corrected for serum albumin), Magnesium and Phosphorus&#xD;
             levels: within normal limits or correctable with supplements l.Serum albumin&#xD;
             concentration ≥ 30 g/L m.Serum amylase and serum lipase ≤ ULN n.PTT ≤ 1.5 x ULN and&#xD;
             INR ≤ 1.3 (unless receiving therapeutic anticoagulants)&#xD;
&#xD;
          4. Contraceptive measures&#xD;
&#xD;
               -  Women of childbearing potential and men must agree to use at least two highly&#xD;
                  effective forms of contraception throughout the entire clinical trial period and&#xD;
                  for 90d post-treatment completion.&#xD;
&#xD;
               -  Men whose partners could be of childbearing potential must routinely use a condom&#xD;
                  throughout the clinical trial period and for 90d posttreatment completion. The&#xD;
                  partner should also use a reliable form of contraception.&#xD;
&#xD;
          5. Signed informed consent&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          1. Medical History&#xD;
&#xD;
               1. Patients with symptomatic CNS metastases (neurologically unstable or requiring&#xD;
                  increasing doses of steroids to control their CNS disease)&#xD;
&#xD;
               2. Hypersensitivity to any of the excipients of CB-103&#xD;
&#xD;
               3. Patients with unresolved nausea, vomiting, or diarrhoea of CTCAE grade &gt; 1&#xD;
&#xD;
               4. Impairment of GI function or presence of GI disease that may significantly alter&#xD;
                  the absorption of CB-103&#xD;
&#xD;
               5. History of second or other primary cancer with the exception of:&#xD;
&#xD;
                    -  Curatively treated non-melanomatous skin cancer&#xD;
&#xD;
                    -  Curatively treated cervical cancer or breast carcinoma in situ&#xD;
&#xD;
                    -  Other primary solid tumour treated with curative intent and no known active&#xD;
                       disease present and no treatment administered during the last 2 years.&#xD;
&#xD;
          2. Exclusionary concurrent medical conditions Impaired cardiac function or clinically&#xD;
             significant cardiac diseases.&#xD;
&#xD;
          3. Prior Therapy&#xD;
&#xD;
               -  Cytotoxic chemotherapy within 3 weeks&#xD;
&#xD;
               -  Any investigational treatment (including NOTCH signaling inhibitors and prior&#xD;
                  treatment with CB-103) within 4 weeks of scheduled CB-103 dosing day 1&#xD;
&#xD;
               -  Concurrent enrolment in another therapeutic clinical trial involving ongoing&#xD;
                  therapy with any investigational or marketed product or placebo&#xD;
&#xD;
               -  Radiation therapy within 2 weeks of scheduled CB-103 dosing day 1&#xD;
&#xD;
               -  Immunotherapy, biological therapies, targeted small molecules, hormonal therapies&#xD;
                  within 3 weeks of scheduled CB-103 dosing day 1&#xD;
&#xD;
               -  Unresolved toxicity CTCAE grade &gt; 1 from previous anti-cancer therapy or&#xD;
                  radiotherapy (excluding neurotoxicity, alopecia, ototoxicity, lymphopenia), or&#xD;
                  incomplete recovery from previous surgery.&#xD;
&#xD;
          4. Current medications&#xD;
&#xD;
               -  Drugs which prolong QT interval&#xD;
&#xD;
               -  Acid reducing agents&#xD;
&#xD;
               -  Patients receiving warfarin and phenytoin that cannot be discontinued at least&#xD;
                  one week prior to start of treatment with CB-103 and for the duration of the&#xD;
                  study&#xD;
&#xD;
               -  Anticoagulants.&#xD;
&#xD;
          5. Demography&#xD;
&#xD;
             - Patients who are pregnant or breast feeding.&#xD;
&#xD;
          6. Others - Patients who are unable or unwilling to comply with all study requirements&#xD;
             for clinical visits, examinations, tests, and procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Florian Vogl, MD, PhD</last_name>
    <phone>+41 61 6332957</phone>
    <email>florian.vogl@cellestia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sarcoma Oncology Research Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht Cancer Center</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Instituto Oncológico Baselga. IOB</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institute of Oncology (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid tumours</keyword>
  <keyword>haematological malignancies</keyword>
  <keyword>phase I/II</keyword>
  <keyword>NOTCH pathway</keyword>
  <keyword>pan-NOTCH inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Glomus Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

